Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE In this review, we first summarize our traditional understanding of the physiology of GIP and GLP-1, and our current knowledge of the relationships between GIP and GLP-1 and obesity and diabetes. 31392745 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Glucagon-like peptide-1 (GLP-1) has attracted tremendous attention for treatment of diabetes. 31376318 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE These concepts are placed within the context of both normal physiology and the pathophysiology of disease, and then extended to discuss emerging strategies that incorporate glucagon agonism in the pharmacology of treating diabetes. 31178432 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 AlteredExpression disease BEFREE These studies highlight the clear, and persistent, metabolic advantages of sustained activation of GLP-1 receptors, alongside concurrent activation of related GIP and xenin cell signalling pathways, in diabetes. 31756326 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE While GIP shares common actions on the pancreatic beta cell with glucagon-like peptide-1 (GLP-1), unlike GLP-1, GIP presents a complex target for the development of diabetes and obesity therapies due to its extra-pancreatic effects on fat mass. 31697967 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy. 31815785 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE In several human studies, GLP-1 secretory responses to oral glucose load or a meal were decreased in subjects with obesity, glucose intolerance, or diabetes compared with those in healthy subjects. 31636017 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Glucagon signaling increases hepatic glucose output, and hyperglucagonemia is partly responsible for the hyperglycemia in diabetes making glucagon an attractive target for therapeutic intervention. 31653720 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE The statistical correlation in glucagon levels between annual checkups and the sustained significant correlation between glucagon and blood urea nitrogen suggest a constant dysregulation of glucagon in association with altered amino acid metabolism in patients with type 1 diabetes. 31465632 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Insulin and glucagon oppositely modulate blood glucose levels in health, but a combined decline in insulin secretion together with increased glucagon secretion contribute to hyperglycemia in diabetes. 31180589 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Alpha-cell lineage tracing revealed that induction of diabetes was accompanied by increased (P < 0.01) transdifferentiation of glucagon positive alpha-cells to insulin positive beta-cells. 31738969 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE The present study aims to investigate the hypoglycemic mechanisms of DOP based on the glucagon-mediated signaling pathways and the liver glycogen structure, which catalyze hepatic glucose metabolism, and provide new knowledge about the antidiabetic mechanism of DOP and further evidence for its clinical use for diabetes. 31622745 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Also, attention was diverted away from GIP by the successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, and a therapeutic strategy for GIP became uncertain when evidence emerged that both inhibition and enhancement of GIP action could prevent or reverse obese non-insulin dependent forms of diabetes in rodents. 31756366 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE GLP-1 therapy is effective concerning weight loss in overweight patients and is more often used in females and patients with shorter diabetes duration. 31471633 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Individual without diabetes remission after gastric bypass have poorer β-cell response and lesser suppression of glucagon to an oral challenge; body weight and incretins differ minimally according to remission status. 31245904 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE The role of glucagon abnormality has recently been reported in type 2 diabetes; however, its role in gestational diabetes mellitus (GDM) is still unknown. 31179612 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE The discovery of incretins (including GLP-1 and GIP) provides a novel therapy for the treatment of diabetes. 31785994 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Exendin-4 is a protein of the GLP-1 family currently used to treat diabetes. 30396070 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE To determine the effect of exercise on plasma glucose, insulin, and glucagon concentrations in ITxs compared with control subjects (CONs) without diabetes. 30403817 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Although agents based on glucagon-like peptide-1 (GLP-1) are now in routine use for diabetes and obesity, the limited efficacy of such drugs means that newer agents are required. 30466162 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Diabetes is a chronic disease, and metabolic factors affecting brain metabolisms, such as serum glucose, insulin, and glucagon, are altered according to disease progression. 31675964 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE GLP-1, a peptide hormone secreted from the gut stimulating insulin and suppressing glucagon secretion was identified as a parent compound for novel treatments of diabetes, but was degraded (dipeptidyl peptidase-4) eliminated (mainly kidneys) too fast (half-life 1-2 min) to be useful as a therapeutic agent. 31600725 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 AlteredExpression disease BEFREE Diabetes increases the severity of impairment in PD, and GLP-1 improve it through its direct neuronal effect in addition to its indirect effect through producing hypoglycemia. 31654678 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Diabetes is a bihormonal disorder resulting from combined insulin and glucagon secretion defects. 30415925 2019
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Our aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD. 31586493 2019